Lumiracoxib
A selective COX-2 inhibitor developed for osteoarthritis and acute pain, offering anti-inflammatory effects with reduced gastrointestinal side effects compared to traditional NSAIDs. It was withdrawn from most markets due to hepatotoxicity concerns.
Peso molecular
293,7200 g/mol
LogP
4,20
TPSA
49,30 Ų
Regla de cinco de Lipinski
Cumple
Áreas terapéuticas
Mecanismo de acción
Inhibits cyclooxygenase (COX-1 and/or COX-2) enzymes, reducing the synthesis of prostaglandins and thromboxanes from arachidonic acid. This produces anti-inflammatory, analgesic, and antipyretic effects.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Inhibits cyclooxygenase (COX-1 and/or COX-2) enzymes, reducing the synthesis of prostaglandins and thromboxanes from arachidonic acid. This produces anti-inflammatory, analgesic, and antipyretic effects.
Estructura 2D
Cite this structure
Embed this structure
SMILES
Cc1ccc(Nc2c(F)cccc2Cl)c(CC(=O)O)c1
InChI
InChI=1S/C15H13ClFNO2/c1-9-5-6-13(10(7-9)8-14(19)20)18-15-11(16)3-2-4-12(15)17/h2-7,18H,8H2,1H3,(H,19,20)
Molecular Formula
C15H13ClFNO2
HBD / HBA
2 / 4
Enlaces Rotables
4
Átomos Pesados
20
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Preguntas frecuentes
A selective COX-2 inhibitor developed for osteoarthritis and acute pain, offering anti-inflammatory effects with reduced gastrointestinal side effects compared to traditional NSAIDs. It was withdrawn from most markets due to hepatotoxicity concerns.
Inhibits cyclooxygenase (COX-1 and/or COX-2) enzymes, reducing the synthesis of prostaglandins and thromboxanes from arachidonic acid. This produces anti-inflammatory, analgesic, and antipyretic effects.
Yes, Lumiracoxib is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL404108. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 151166. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="lumiracoxib"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/lumiracoxib/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/lumiracoxib/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/lumiracoxib/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="lumiracoxib"></drugfyi-drug>